BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15781616)

  • 1. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.
    Chuu CP; Hiipakka RA; Fukuchi J; Kokontis JM; Liao S
    Cancer Res; 2005 Mar; 65(6):2082-4. PubMed ID: 15781616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
    Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
    Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.
    Jennbacken K; Gustavsson H; Tesan T; Horn M; Vallbo C; Welén K; Damber JE
    Prostate; 2009 Aug; 69(11):1164-75. PubMed ID: 19399749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist.
    Chuu CP; Hiipakka RA; Kokontis JM; Fukuchi J; Chen RY; Liao S
    Cancer Res; 2006 Jul; 66(13):6482-6. PubMed ID: 16818617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen-dependent regulation of Her-2/neu in prostate cancer cells.
    Berger R; Lin DI; Nieto M; Sicinska E; Garraway LA; Adams H; Signoretti S; Hahn WC; Loda M
    Cancer Res; 2006 Jun; 66(11):5723-8. PubMed ID: 16740710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
    Harper ME; Goddard L; Smith C; Nicholson RI
    Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
    Umekita Y; Hiipakka RA; Kokontis JM; Liao S
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11802-7. PubMed ID: 8876218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype.
    Butterworth KT; McCarthy HO; Devlin A; Ming L; Robson T; McKeown SR; Worthington J
    Int J Cancer; 2008 Aug; 123(4):760-8. PubMed ID: 18512241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C
    Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
    Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
    Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
    Nagabhushan M; Miller CM; Pretlow TP; Giaconia JM; Edgehouse NL; Schwartz S; Kung HJ; de Vere White RW; Gumerlock PH; Resnick MI; Amini SB; Pretlow TG
    Cancer Res; 1996 Jul; 56(13):3042-6. PubMed ID: 8674060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
    Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
    Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.
    Sato N; Gleave ME; Bruchovsky N; Rennie PS; Goldenberg SL; Lange PH; Sullivan LD
    J Steroid Biochem Mol Biol; 1996 May; 58(2):139-46. PubMed ID: 8809195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
    Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.